全文获取类型
收费全文 | 112645篇 |
免费 | 6880篇 |
国内免费 | 678篇 |
专业分类
耳鼻咽喉 | 1149篇 |
儿科学 | 3658篇 |
妇产科学 | 2636篇 |
基础医学 | 16282篇 |
口腔科学 | 4168篇 |
临床医学 | 10406篇 |
内科学 | 24912篇 |
皮肤病学 | 2845篇 |
神经病学 | 11299篇 |
特种医学 | 2588篇 |
外国民族医学 | 1篇 |
外科学 | 10211篇 |
综合类 | 420篇 |
一般理论 | 53篇 |
预防医学 | 11158篇 |
眼科学 | 1783篇 |
药学 | 8112篇 |
中国医学 | 453篇 |
肿瘤学 | 8069篇 |
出版年
2023年 | 1016篇 |
2022年 | 893篇 |
2021年 | 3456篇 |
2020年 | 2516篇 |
2019年 | 3370篇 |
2018年 | 3821篇 |
2017年 | 2889篇 |
2016年 | 3322篇 |
2015年 | 3701篇 |
2014年 | 4916篇 |
2013年 | 6385篇 |
2012年 | 9712篇 |
2011年 | 10103篇 |
2010年 | 5467篇 |
2009年 | 4629篇 |
2008年 | 7960篇 |
2007年 | 8006篇 |
2006年 | 7297篇 |
2005年 | 6837篇 |
2004年 | 6158篇 |
2003年 | 5451篇 |
2002年 | 4898篇 |
2001年 | 551篇 |
2000年 | 364篇 |
1999年 | 552篇 |
1998年 | 663篇 |
1997年 | 555篇 |
1996年 | 446篇 |
1995年 | 486篇 |
1994年 | 459篇 |
1993年 | 381篇 |
1992年 | 297篇 |
1991年 | 203篇 |
1990年 | 205篇 |
1989年 | 188篇 |
1988年 | 177篇 |
1987年 | 149篇 |
1986年 | 162篇 |
1985年 | 120篇 |
1984年 | 140篇 |
1983年 | 134篇 |
1982年 | 168篇 |
1981年 | 121篇 |
1980年 | 129篇 |
1979年 | 80篇 |
1978年 | 80篇 |
1977年 | 72篇 |
1976年 | 62篇 |
1975年 | 47篇 |
1974年 | 54篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Malou A.H. Nuijten Thijs M.H. Eijsvogels Valerie M. Monpellier Ignace M.C. Janssen Eric J. Hazebroek Maria T.E. Hopman 《Obesity reviews》2022,23(1):e13370
Postbariatric loss of muscle tissue could negatively affect long-term health due to its role in various bodily processes, such as metabolism and functional capacity. This meta-analysis aimed to unravel time-dependent changes in the magnitude and progress of lean body mass (LBM), fat-free mass (FFM), and skeletal muscle mass (SMM) loss following bariatric surgery. A systematic literature search was conducted in Pubmed, Embase, and Web of Science. Fifty-nine studies assessed LBM (n = 37), FFM (n = 20), or SMM (n = 3) preoperatively and ≥1 time points postsurgery. Random-effects meta-analyses were performed to determine pooled loss per outcome parameter and follow-up time point. At 12-month postsurgery, pooled LBM loss was ?8.13 kg [95%CI ?9.01; ?7.26]. FFM loss and SMM loss were ?8.23 kg [95%CI ?10.74; ?5.73] and ?3.18 kg [95%CI ?5.64; ?0.71], respectively. About 55% of 12-month LBM loss occurred within 3-month postsurgery, followed by a more gradual decrease up to 12 months. Similar patterns were seen for FFM and SMM. In conclusion, >8 kg of LBM and FFM loss was observed within 1-year postsurgery. LBM, FFM, and SMM were predominantly lost within 3-month postsurgery, highlighting that interventions to mitigate such losses should be implemented perioperatively. 相似文献
2.
3.
Rizzo Giuseppe Pietrolucci Maria Elena Capponi Alessandra Mappa Ilenia 《The international journal of cardiovascular imaging》2022,38(5):1017-1019
The International Journal of Cardiovascular Imaging - 相似文献
4.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
5.
Lesmana Cosmas Rinaldi Adithya Paramitha Maria Satya Gani Rino A. Lesmana Laurentius A. 《Journal of Medical Ultrasonics》2022,49(3):359-370
Journal of Medical Ultrasonics - Chronic liver disease is still a major problem because disease progression will ultimately lead to liver cirrhosis. Portal hypertension is the hallmark in advanced... 相似文献
6.
Anne-Sophie Worm Fenger Markus Harboe Olsen Maria Louise Fabritius Christian Gunge Riberholt Kirsten Møller 《Acta anaesthesiologica Scandinavica》2023,67(2):240-247
Background
Hyperglycaemia is common in patients with acute brain injury admitted to an intensive care unit (ICU). Many studies have found associations between development of hyperglycaemia and increased mortality in hospitalised patients. However, the optimal target for blood glucose control is unknown. We want to conduct a systematic review with meta-analysis and trial sequential analysis to explore the beneficial and harmful effects of restrictive versus liberal glucose control on patient outcomes in adults with severe acute brain injury.Methods
We will systematically search medical databases including CENTRAL, Embase, MEDLINE and trial registries. We will search the following websites for ongoing or unpublished trials: http://www.controlled-trials.com/ , http://www.clinicaltrials.gov/ , www.eudraCT.com , http://centerwatch.com/ , The Cochrane Library's CENTRAL, PubMed, EMBASE, Science Citation Index Expanded and CINAHL. Two authors will independently review and select trials and extract data. We will include randomised trials comparing levels of glucose control in our analyses and observational studies will be included to address potential harms. The primary outcomes are defined as all-cause mortality, functional outcome and health-related quality of life. Secondary outcomes include serious adverse events including hypoglycaemia, length of ICU stay and duration of mechanical ventilation, and explorative outcomes including intracranial pressure and infection. Trial Sequential Analysis will be used to investigate the risk of type I error due to repetitive testing and to further explore imprecision. Quality of trials will be evaluated using the Cochrane Risk of Bias tool, and quality of evidence will be assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach.Discussion
The results of the systematic review will be disseminated through peer-reviewed publication. With the review, we hope to inform future randomised clinical trials and improve clinical practice. 相似文献7.
8.
Francisco Javier P rez Lara Maria Belen Jimenez Martinez Francisco Pozo Mu oz res Fontalba Navas Rogelio Garcia Cisneros Maria Jose Garcia Larrosa Ignacio Garcia Delgado Maria del Mar Callejon Gil 《World Journal of Clinical Cases》2021,9(23):6582-6590
The coronavirus disease 2019, which is caused by severe acute respiratory syndrome coronavirus 2, was first identified in December 2019 in Wuhan, China, and has since spread rapidly, evolving into a full-blown pandemic. We would like to report our experience after 1 year of this pandemic in the surgical service of a district hospital in Spain. There have been many changes (including new protocols) that our service and the hospital have undergone, to adapt to the new situation. We believe that this experience can be useful for other professionals who have lived and are living a similar situation. 相似文献
9.
Emilie M.J. van Brummelen Sanne Huijberts Carla van Herpen Ingrid Desar Frans Opdam Robin van Geel Serena Marchetti Neeltje Steeghs Kim Monkhorst Bas Thijssen Hilde Rosing Alwin Huitema Jos Beijnen Rene Bernards Jan Schellens 《The oncologist》2021,26(4):290-e545
Lessons Learned
- Afatinib and selumetinib can be combined in continuous and intermittent dosing schedules, albeit at lower doses than approved for monotherapy.
- Maximum tolerated dose for continuous and intermittent schedules is afatinib 20 mg once daily and selumetinib 25 mg b.i.d.
- Because the anticancer activity was limited, further development of this combination is not recommended until better biomarkers for response and resistance are defined.